Clinical trial coding vs healthcare reimbursement coding

Medical coding in clinical research serves a completely different objective from healthcare billing. While hospital and provider coding (ICD-10-CM, CPT, HCPCS Level II) focuses on insurance claims, fee schedules, and reimbursement, clinical trial coding focuses on patient safety, trial protocol standardization, and regulatory compliance.

During a clinical trial, investigator sites worldwide record patient observations in unstructured text. Medical coding transforms these free-text entries into standardized, universally understood alphanumeric codes stored in Electronic Data Capture (EDC) systems.

MedDRA: Coding adverse events and medical conditions

The Medical Dictionary for Regulatory Activities (MedDRA), maintained by the International Council for Harmonisation (ICH), is the global standard for coding adverse events (AEs), symptoms, and diagnoses in clinical trials.

MedDRA operates across a 5-tier hierarchy: System Organ Class (SOC) at the broadest anatomical level, down through High-Level Group Terms (HLGT), High-Level Terms (HLT), Preferred Terms (PT), and Lowest Level Terms (LLT). This multi-level structure allows biostatisticians and safety monitors to detect adverse safety signals at both granular and systemic levels.

WHODrug: Standardizing concomitant medications

The WHODrug Dictionary, maintained by the Uppsala Monitoring Centre (UMC), standardizes all prior and concomitant medications taken by clinical trial participants.

WHODrug maps trade names, active chemical ingredients, and Anatomical Therapeutic Chemical (ATC) classifications. This allows clinical data managers to assess potential drug-drug interactions and monitor compliance with protocol exclusion criteria.

From investigational candidate to commercial NDC and J-Code

Throughout Phase 1, Phase 2, and Phase 3 clinical studies, an investigational product operates under an FDA Investigational New Drug (IND) application, identified by protocol research codes.

Once a candidate proves safety and efficacy in Phase 3 trials and receives FDA approval (via NDA or BLA), it enters the commercial healthcare system. The manufacturer registers the product with the FDA to receive a National Drug Code (NDC), CMS assigns a permanent HCPCS Level II J-code for clinician administration, and the AMA designates CPT procedure codes for administration.